Smith Salley Wealth Management Acquires New Stake in AstraZeneca PLC $AZNCF

Smith Salley Wealth Management bought a new position in shares of AstraZeneca PLC (OTCMKTS:AZNCF) during the 1st quarter, HoldingsChannel reports. The institutional investor bought 68,919 shares of the company’s stock, valued at approximately $13,592,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Monetary Management Group Inc. purchased a new position in shares of AstraZeneca in the fourth quarter valued at approximately $1,097,000. L & S Advisors Inc acquired a new position in shares of AstraZeneca in the fourth quarter valued at approximately $14,863,000. Seven Mile Advisory purchased a new stake in AstraZeneca during the 4th quarter worth approximately $738,000. Oarsman Capital Inc. purchased a new stake in AstraZeneca during the 4th quarter worth approximately $5,027,000. Finally, Hendley & Co. Inc. acquired a new stake in AstraZeneca during the 4th quarter worth approximately $11,373,000. 40.87% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Stock Performance

AstraZeneca stock opened at $187.10 on Monday. AstraZeneca PLC has a 52-week low of $122.26 and a 52-week high of $195.00. The company’s 50 day moving average is $187.10 and its two-hundred day moving average is $186.05.

AstraZeneca Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.